Monarc Bionetworks, of Palo Alto, Calif., said it initiated a strategic integration with the drug development platform of Roivant Sciences Ltd., of Basel, Switzerland. Monarc's team has built disease-specific patient network applications and online tools that prequalify and engage patients during protocol development prior to study initiation.